Northrop Grumman Corporation
551.44USD
-0.9100 (-0.16%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NOC.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 36.6B | 39.3B | 41.0B | 42.0B | 44.1B | 46.9B |
| Q1 | 8.8B | 9.3B | 10.1B | 9.5B | 9.9B | 10.4B |
| Q2 | 8.8B | 9.6B | 10.2B | 10.4B | 10.9B | — |
| Q3 | 9.0B | 9.8B | 10.0B | 10.4B | 11.1B | — |
| Q4 | 10.0B* | 10.6B* | 10.7B* | 11.7B* | 12.2B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 31.47 | 13.53 | 28.34 | 29.08 | 29.75 | 30.03 |
| Q1 | 6.10 | 5.50 | 6.32 | 3.32 | 6.14 | 6.43 |
| Q2 | 6.06 | 5.34 | 6.36 | 8.15 | 7.68 | — |
| Q3 | 5.89 | 6.18 | 7.00 | 7.67 | 7.89 | — |
| Q4 | 13.37* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -3.52* |
| 8.58* |
| 9.92* |
| 7.93 |
| — |
Debt level and coverage